Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
The PIONEER series (oral semaglutide) and SUSTAIN series (injectable semaglutide) provide evidence that injections consistently outperform tablets across weight loss, glycemic control, and cardiovascular outcomes in diabetes populations
Key Points Summary Asias GLP1 uptake has lagged the West but is primed for rapid acceleration as obesity rates rise and government urgency grows China and India are driving demand shifts as diets westernise and metabolic disease climbs Cost barriers are falling: local firms in China and India are developing cheaper semaglutide generics, forcing price cuts Mintel forecasts explosive growth, with China potentially becoming the worlds No1 GLP1 market by 2030 Safety fears persist in China (side effects, rebound, semaglutide face) and in India (strict rules on drug promotion) GLP-1 agonist drugs have revolutionised weight loss in the United States and parts of Europe, providing in most cases a highly effective way to manage the ballooning issue of obesity in these markets
Its highly doubtful that all of the drugs people take will be for sale through this channel, Cubanski said
More steps mean more purification cycles, more quality control checkpoints, and more opportunities for synthesis to fail
In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal
